Form 8-K for Bodisen Biotech
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): October 18, 2006
BODISEN
BIOTECH, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
333-99101
|
98-0381367
|
|
(State
or Other Jurisdiction
|
(Commission File
|
(I.R.S.
Employer
|
|
of
Incorporation)
|
Number)
|
Identification
Number)
|
North
Part of Xinquia Road, Yang Ling Agricultural High-Tech
Industries
Demonstration Zone, Yang Ling,
People's
Republic of China 712100
(Address
of principal executive offices) (zip code)
86-29-87074957
(Registrant's
telephone number, including area code)
Copies
to:
Marc
J.
Ross, Esq.
Yoel
Goldfeder, Esq.
Sichenzia
Ross Friedman Ference LLP
1065
Avenue of the Americas
New
York,
New York 10018
Phone:
(212) 930-9700
Fax:
(212) 930-9725
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[
]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[
]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[
]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
[
]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure
On
October 18, 2006, we provided forward guidance with regard to our strong
revenues and net income growth for our third quarter ended September 30, 2006.
A
copy of the press release that discusses this matter is filed as Exhibit 99.1
to, and incorporated by reference in, this report. In accordance with Regulation
FD, this current report is being filed to publicly disclose all information
that
was provided in its press release. This report under Item 7.01 is not deemed
an
admission as to the materiality of any information in this report that is
required to be disclosed solely by Regulation FD.
Item
9.01 Financial Statements and Exhibits.
|
Exhibit
Number
|
|
Description
|
|
99.1
|
|
Press
Release, dated October 18, 2006, issued by Bodisen Biotech,
Inc.
|
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
|
|
| |
BODISEN
BIOTECH,
INC. |
|
|
|
| Date: October
18, 2006 |
By: |
/s/ Qiong
Wang |
| |
Name:
Qiong
Wang |
| |
Title:
Chief
Executive Officer |